Bruce Wilson, MD
Endocrinology, Diabetes & Metabolism · Richland, WANPI 1295826857
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $264,045 of the $352,273 with a category attached, or 75.0%. 40 manufacturers reported payments, led by Novo Nordisk at 34.3% of the total. Reporting peaked in 2019 at $117,142 and has fallen 74.3% since, to $30,051 in 2025. Among endocrinology, diabetes & metabolism clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,091 payments — averaging $322.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$121K
- Abbott$46K
- Boehringer Ingelheim$41K
- Lilly USA, LLC$35K
- Sanofi-aventis U.S. LLC$33K
- Merck$20K
- plus $57K from 34 others
What the payments were for
- Consulting fees$13,0134%
- Speaking & faculty fees$264,04575%
- Travel & lodging$54,25915%
- Food & beverage$20,8266%
- Education$1310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$70,562
- Ozempic$55,247
- RYBELSUS$31,204
- FREESTYLE LIBRE 3$28,817
- STEGLATRO$19,353
- SOLIQUA 100/33$19,019
- Tresiba$18,442
- INVOKANA$16,146
- FreeStyle Libre Pro$13,341
- Kerendia$12,857
- TOUJEO$12,254
- Korlym$6,025
- GVOKE PFS$5,334
- Xultophy 100/3.6$4,610
- FreeStyle Libre$2,600
- Minimed 630G$2,500
- TEPEZZA$2,085
- InPen$2,000
- NATPARA (PARATHYROID HORMONE)$1,000
- FARXIGA$591
How this compares
$352,273 in reported general payments places this provider in the 95th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 889 | $1,378,121 |
| JardianceEmpagliflozin | 325 | $426,162 |
| Tresiba Flextouch U-200Insulin Degludec | 206 | $214,860 |
| FarxigaDapagliflozin Propanediol | 117 | $129,913 |
| TrulicityDulaglutide | 60 | $129,691 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 80 | $113,421 |
| MounjaroTirzepatide | 61 | $112,206 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 46 | $67,132 |
| RybelsusSemaglutide | 25 | $46,762 |
| ProliaDenosumab | 24 | $40,918 |
| InvokanaCanagliflozin | 22 | $38,226 |
| Humalog Kwikpen U-100Insulin Lispro | 88 | $32,426 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 39 | $30,237 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 165 | $29,124 |
| HumalogInsulin Lispro | 86 | $28,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $120,716 | $1,471,324968 claims |
| Boehringer IngelheimJardiance | $40,839 | $426,162325 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $35,013 | $273,296227 claims |
| AstraZenecaFarxiga | $1,756 | $129,913117 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $33,432 | $72,29358 claims |
| AmgenProlia | $4,097 | $40,91824 claims |
| Johnson & JohnsonInvokana | $16,300 | $38,22622 claims |
| BayerKerendia | $12,954 | $20,72311 claims |
| AbbVieSynthroid | $279 | $10,635120 claims |
| MerckJanuvia | $19,723 | $8,09114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Richland
- Michael ShannonLacey$698K
- Lynn KohlmeierSpokane$518K
- Carol WyshamSpokane$512K
- Irl HirschSeattle$192K
- Biju KunhiramanYakima$118K
- Nicole EhrhardtSeattle$111K
- Kristina UtzschneiderSeattle$72K
- Savitha SubramanianSeattle$71K
- Sonia HansKirkland$70K
- George MooreBothell$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.